Radionuclide-loaded nanoparticles for focal tissue ablation
View Patent ↗The present disclosure features radiopharmaceutical compositions including a radionuclide and an imaging agent encapsulated within, embedded in, or conjugated to a nanoparticle (e.g., via a complexing moiety, such as a chelator), and methods of their use. The radiopharmaceuticals may be formulated for direct administration to the diseased tissue, with minimal or no washout of the radiopharmaceutical to non-target sites within a subject. The radiopharmaceuticals of the present disclosure allow for efficient treatment of diseased tissue proximal to the site of administration with minimal to no damage to the surrounding tissue.
1. A radiopharmaceutical comprising:
(a) a plurality of non-encapsulated nanoparticles, each comprising a matrix with an exterior surface;
(b) an imaging agent;
(c) a radionuclide bound to a chelating agent; and
(d) a cell-penetrating ligand;
wherein, for each nanoparticle of the plurality of nanoparticles, the imaging agent and the radionuclide are encapsulated within the nanoparticle and the cell-penetrating ligand is conjugated to the exterior surface of the nanoparticle,
wherein each said nanoparticle is from about 1 nm to about 900 nm in diameter,
wherein the radiopharmaceutical has a radioactivity of greater than 0.125 kBq per mL, and
wherein the cell-penetrating ligand promotes nuclear localization of the nanoparticle.
2. The radiopharmaceutical of claim 1 , wherein the matrix of the nanoparticle is a polymer matrix comprising hyaluronic acid (HA), polyethylene glycol diacrylate (PEGDA), polyglycolic acid (PGA), polylactic acid (PLA), poly (lactic-co-glycolic acid) (PLGA), polysaccharide, polycaprolactone (PCL), collagen, gelatin, poly (methyl methacrylate) (PMMA), polystyrene, carboxymethyl chitosan (CCN), carboxymethyl cellulose (CMC), phospholipids, or a combination thereof.
3. The radiopharmaceutical of claim 1 , wherein the imaging agent comprises a phospholipid, ferumoxytol, Gadolinium, Holmium, Europium, Thulium, Cu-64, Tc-99m, In-111, lodixanol, lohexol or a derivative thereof, lohexol related compound B or a derivative thereof, or a combination thereof; and wherein the imaging agent is amenable to visualization with an imaging modality selected from the group consisting of ultrasound, fluoroscopy, computed tomography, magnetic resonance imaging, single photon emission computed tomography, positron emission tomography, or a combination thereof.
4. The radiopharmaceutical of claim 1 , wherein the radionuclide is a therapeutic radionuclide.
5. The radiopharmaceutical of claim 1 , wherein the radionuclide is an a-emitting radionuclide, a β-emitting radionuclide, or an Auger electron emitting radionuclide.
6. The radiopharmaceutical of claim 1 , wherein the radionuclide is an α-emitting radionuclide.
7. The radiopharmaceutical of claim 1 , wherein the radionuclide undergoes radioactive decay to produce a daughter nucleus, and wherein the daughter nucleus is a therapeutic radionuclide, comprising an α-emitting radionuclide, a β-emitting radionuclide, or an Auger electron emitting radionuclide.
8. The radiopharmaceutical of claim 7 , wherein the daughter nucleus comprises an α-emitting radionuclide.
9. The radiopharmaceutical of claim 1 , wherein the radionuclide comprises terbium-149, astatine-211, bismuth-212, lead-212, bismuth-213, radium-223, radium-224, actinium-225, thorium-227, yittrium-90, iodine-131, holmium-166, lutetium-177, or a combination thereof.
10. The radiopharmaceutical of claim 1 , wherein each said nanoparticle of the plurality of nanoparticles further comprises a complexing moiety bound to the exterior surface of the nanoparticle, wherein the complexing moiety is diethylenetriaminepentaacetate (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA), ethylenediamine tetraacetate (EDTA), cis-1,3,5-cyclohexantriamine (CHTA), triethylene glycol diamine tetraacetate (EGTA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetate (TETA), 1,4,7,10-tetraazacyclododecane -1,4,7-triacetate (DO3A), 1,4,7-triazacyclononane-1,4,7-triacetate (NOTA), 1,4,7,10,13,16-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetate (HEHA), N,N′-[(6-carboxy-2-pyridyl (methyl)]-4,13-diaza-18-crown-6 (MACROPA), a reactive derivative thereof, or a combination thereof.
11. The radiopharmaceutical of claim 10 , wherein the complexing moiety is conjugated to the nanoparticle through a covalent bond or an ionic bond, wherein optionally, the complexing moiety conjugates the cell-penetrating ligand to the exterior of the nanoparticle.
12. The radiopharmaceutical of claim 1 , wherein the cell-penetrating ligand is transactivating transcriptional activator (TAT), herpes simplex virus (HSV), glycoprotein H (gH) domain of herpes simplex virus 1 (gH625), penetratin, VP22, transportan, or a combination thereof.
13. The radiopharmaceutical of claim 1 , further comprising a sub-nanoparticle encapsulated within the nanoparticle, wherein the sub-nanoparticle comprises:
(a) a sub-nanoparticle matrix comprising an exterior surface, wherein the sub-nanoparticle matrix comprises a metal matrix or a polymer matrix; and
(b) an imaging agent capable of being visualized with an imaging modality;
wherein the radionuclide of the radiopharmaceutical is localized to the sub-nanoparticle.
14. The radiopharmaceutical of claim 13 , wherein the sub-nanoparticle matrix comprises iron, gold, platinum, tantalum, magnetite (Fe 3 O 4 ), maghemite (γ-Fe 2 O 3 ), hematite (α-Fe 2 O 3 ), hyaluronic acid (HA), polyethylene glycol diacrylate (PEGDA), polyglycolic acid (PGA), polylactic acid (PLA), poly (lactic-co-glycolic acid) (PLGA), polysaccharide, polycaprolactone (PCL), Collagen, Gelatin, poly (methyl methacrylate) (PMMA), polystyrene, carboxymethyl chitosan (CCN), carboxymethyl cellulose (CMC), phospholipids, or a combination thereof.
15. The radiopharmaceutical of claim 13 , wherein the sub-nanoparticle has a diameter of from about 1 nm to about 10 nm.
16. The radiopharmaceutical of claim 13 , wherein the imaging agent of the sub-nanoparticle comprises a phospholipid, ferumoxytol, Gadolinium, Holmium, Europium, Thulium, Cu-64, Tc-99m, In-111, lodixanol, lohexol or a derivative thereof, lohexol related compound B or a derivative thereof, or a combination thereof; and/or the imaging modality for imaging the sub-nanoparticle is ultrasound, fluoroscopy, computed tomography, magnetic resonance imaging, single photon emission computed tomography, positron emission tomography, or a combination thereof.
17. The radiopharmaceutical of claim 13 , wherein the sub-nanoparticle further comprises a complexing moiety, wherein the complexing moiety is bound to the exterior surface of the sub-nanoparticle and to a second radionuclide, wherein the complexing moiety of the sub-nanoparticle is a chelator, and wherein the chelator is DTPA, DOTA, EDTA, CHTA, EGTA, TETA, DO3A, NOTA, HEHA, MACROPA, a reactive derivative thereof, or a combination thereof.
18. The radiopharmaceutical of claim 17 , wherein the second radionuclide is conjugated to the exterior surface of the sub-nanoparticle via the complexing moiety.
19. The radiopharmaceutical of claim 13 , wherein the sub-nanoparticle further comprises a cell-penetrating ligand covalently attached to the exterior surface of the sub-nanoparticle.
20. The radiopharmaceutical of claim 1 , wherein each said nanoparticle has a specific activity of about 0.01 μBq to about 10 μBq.
21. A pharmaceutical composition comprising the radiopharmaceutical of claim 1 , and a pharmaceutically acceptable excipient.
22. The pharmaceutical composition of claim 21 , wherein the excipient is a polyol, a polyether, salcaprozate sodium, or sodium caprate.
23. A kit comprising:
(a) the radiopharmaceutical of claim 1 ; and
(b) instructions for use thereof,
wherein, optionally, the kit further comprises:
(c) a mixer; and/or
(d) a micro puncture set.
24. A method of treating or diagnosing a disease, condition, or disorder in a subject comprising administering the radiopharmaceutical of claim 1 to a subject in need thereof.
25. The method of claim 24 , wherein the disease, condition, or disorder comprises neoplastic tissue, a malignancy, or cancer.
26. The method of claim 25 , wherein the cancer comprises pancreatic cancer, head and neck cancer, breast cancer, cervical cancer, prostate cancer, retinal cancer, thyroid cancers, lymphomas, meningiomas, brain tumors, or neuroendocrine tumors.
27. The method of claim 24 , wherein the radiopharmaceutical or a pharmaceutical composition comprising the radiopharmaceutical is administered into a diseased tissue, wherein the diseased tissue is a solid tumor.
28. The method of claim 27 , wherein the radiopharmaceutical or the pharmaceutical composition has a radioactive activity of at least 0.125 kBq per mL of the diseased tissue.